Matches in UGent Biblio for { <https://biblio.ugent.be/publication/395170#aggregation> ?p ?o. }
Showing items 1 to 37 of
37
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B333942.
- aggregation creator B333943.
- aggregation creator B333944.
- aggregation creator B333945.
- aggregation creator B333946.
- aggregation creator person.
- aggregation date "2007".
- aggregation format "application/pdf".
- aggregation hasFormat 395170.bibtex.
- aggregation hasFormat 395170.csv.
- aggregation hasFormat 395170.dc.
- aggregation hasFormat 395170.didl.
- aggregation hasFormat 395170.doc.
- aggregation hasFormat 395170.json.
- aggregation hasFormat 395170.mets.
- aggregation hasFormat 395170.mods.
- aggregation hasFormat 395170.rdf.
- aggregation hasFormat 395170.ris.
- aggregation hasFormat 395170.txt.
- aggregation hasFormat 395170.xls.
- aggregation hasFormat 395170.yaml.
- aggregation isPartOf urn:issn:0903-1936.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma".
- aggregation abstract "The present study examined the bronchodilator and safety profiles of single-dose indacaterol in intermittent or persistent asthma. In the present double-blind crossover study, 42 patients were randomised to receive single doses of indacaterol (50, 100, 200 and 400 mu g) or placebo via a hydrofluoroalkane pressurised metered-dose inhaler. The primary efficacy comparisons were the per cent changes in forced expiratory volume in one second (FEV1) between indacaterol and placebo 30 min and 21 h post-dose. All doses resulted in prolonged bronchodilation, with indacaterol 200 and 400 mu g meeting prespecified efficacy criteria. The mean percentage increases in FEV1 from placebo with indacaterol 200 and 400 mu g were 7.6 and 14.9%, respectively, at 30 min, and 7.5 and 10.4%, respectively, at 21 h post-dose. At these doses, changes in mean FEV1 relative to placebo were statistically significant from 5 min to 25 h, inclusive. At 5 min, the geometric least squares mean values for FEV1 were 3.08 and 3.22 L for the 200 and 400 mu g doses, respectively, compared with 2.99 L for placebo. At 24 h after dosing, the baseline-adjusted geometric least square mean FEV1 was 3.13, 3.11, 3.24 and 3.30 L for indacaterol 50, 100, 200 and 400 mu g, respectively, and 2.98 L for placebo. All treatments were well tolerated. Once-daily indacaterol at doses of 200 and 400 mu g provided sustained 24-h bronchodilation, with a rapid onset and a good tolerability and safety profile.".
- aggregation authorList BK629278.
- aggregation endPage "878".
- aggregation issue "5".
- aggregation startPage "871".
- aggregation volume "29".
- aggregation aggregates 1861973.
- aggregation isDescribedBy 395170.
- aggregation similarTo 09031936.00060006.
- aggregation similarTo LU-395170.